Diabetic Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500

Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes.

The Diabetic Macular Edema drugs in development market research report provide comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects.

Key Targets in the Diabetic Macular Edema Pipeline Products Market

The key targets in the Diabetic Macular Edema pipeline products market are Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor, Placenta Growth Factor, Plasma Kallikrein, Glucocorticoid Receptor, Angiopoietin 1 Receptor, Angiopoietin 2, Semaphorin 3A, Vascular Endothelial Growth Factor Receptor, Apoptosis Regulator Bcl 2, and others.

Diabetic Macular Edema Pipeline Products Analysis Market by Targets

Diabetic Macular Edema Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Diabetic Macular Edema Pipeline Products Market

The key mechanisms of action in the Diabetic Macular Edema pipeline products market are Vascular Endothelial Growth Factor A Inhibitor, Vascular Endothelial Growth Factor Inhibitor, Placenta Growth Factor Inhibitor, Plasma Kallikrein Inhibitor, Glucocorticoid Receptor Agonist, Angiopoietin 2 Inhibitor, Semaphorin 3A Inhibitor, Angiopoietin 1 Receptor Agonist, Apoptosis Regulator Bcl 2 Inhibitor, DNA (Apurinic or Apyrimidinic Site) Lyase Inhibitor, and others.

Diabetic Macular Edema Pipeline Products Market Analysis by Mechanism of Actions

Diabetic Macular Edema Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of actions insights, download a free report sample

Key Routes of Administration in the Diabetic Macular Edema Pipeline Products Market

The key routes of administration in the Diabetic Macular Edema pipeline products market are intravitreal, oral, ophthalmic, intraocular, parenteral, topical, intravenous, subcutaneous, buccal, conjunctival, and others.

Diabetic Macular Edema Pipeline Products Market Analysis by Routes of Administration

Diabetic Macular Edema Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Diabetic Macular Edema Pipeline Products Market

The key molecule types in the Diabetic Macular Edema pipeline products market are small molecule, monoclonal antibody, fusion protein, synthetic peptide, gene therapy, recombinant protein, protein, antisense oligonucleotide, aptamer, cell therapy, and others.

Diabetic Macular Edema Pipeline Products Market Analysis by Molecule Type

Diabetic Macular Edema Pipeline Products Market Analysis by Molecule Type

For more molecule type insights, download a free report sample

Major Companies in the Diabetic Macular Edema Pipeline Products Market

Some of the major companies in the Diabetic Macular Edema pipeline products market are F. Hoffmann-La Roche Ltd, ANBITION Srl, Ocular Therapeutix Inc, Ascentage Pharma Group International, Avirmax Inc, Clearside BioMedical Inc, Kalvista Pharmaceuticals Inc, Samsung Bioepis Co Ltd, Aadi Bioscience Inc, and Aerie Pharmaceuticals Inc.

Diabetic Macular Edema Pipeline Products Market Analysis by Companies

Diabetic Macular Edema Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Overview

Key targets Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor, Placenta Growth Factor, Plasma Kallikrein, Glucocorticoid Receptor, Angiopoietin 1 Receptor, Angiopoietin 2, Semaphorin 3A, Vascular Endothelial Growth Factor Receptor, Apoptosis Regulator Bcl 2, and Others
Key mechanism of action Vascular Endothelial Growth Factor A Inhibitor, Vascular Endothelial Growth Factor Inhibitor, Placenta Growth Factor Inhibitor, Plasma Kallikrein Inhibitor, Glucocorticoid Receptor Agonist, Angiopoietin 2 Inhibitor, Semaphorin 3A Inhibitor, Angiopoietin 1 Receptor Agonist, Apoptosis Regulator Bcl 2 Inhibitor, DNA (Apurinic or Apyrimidinic Site) Lyase Inhibitor, and Others
Key routes of administration Intravitreal, Oral, Ophthalmic, Intraocular, Parenteral, Topical, Intravenous, Subcutaneous, Buccal, Conjunctival, and Others
Key molecule type Small Molecule, Monoclonal Antibody, Fusion Protein, Synthetic Peptide, Gene Therapy, Recombinant Protein, Protein, Antisense Oligonucleotide, Aptamer, Cell Therapy, and Others
Major companies F. Hoffmann-La Roche Ltd, ANBITION Srl, Ocular Therapeutix Inc, Ascentage Pharma Group International, Avirmax Inc, Clearside BioMedical Inc, Kalvista Pharmaceuticals Inc, Samsung Bioepis Co Ltd, Aadi Bioscience Inc, and Aerie Pharmaceuticals Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

3SBio Inc
4D Molecular Therapeutics Inc
Aadi Bioscience Inc
Abpro Corp
Aciont Inc
Aerie Pharmaceuticals Inc
Aldeyra Therapeutics Inc
Allegro Ophthalmics LLC
Allgenesis Biotherapeutics Inc
AmMax Bio Inc
Ampio Pharmaceuticals Inc
ANBITION Srl
Apexian Pharmaceuticals Inc
Araim Pharmaceuticals Inc
Ascentage Pharma Group International
AsclepiX Therapeutics Inc
Ashvattha Therapeutics LLC
AskGene Pharma Inc
Avirmax Inc
BetaStem Therapeutics Inc
Bio-Thera Solutions Ltd
BioCryst Pharmaceuticals Inc
Cell Care Therapeutics Inc
Celltrion Inc
Celon Pharma SA
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chiome Bioscience Inc
Clearside BioMedical Inc
Curacle Co Ltd
Drive Therapeutics LLC
Elasmogen Ltd
Eluminex Biosciences Ltd
Everglades Biopharma LLC
Exonate Ltd
EyeGene Inc
F. Hoffmann-La Roche Ltd
Gene Signal International SA
GlaxoSmithKline Plc
Graybug Vision Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Huabo Biopharm (Shanghai) Co Ltd
Huadong Medicine Co Ltd
Ikarovec Ltd
Innovent Biologics Inc
Isarna Therapeutics GmbH
Johnson & Johnson
Kala Pharmaceuticals Inc
Kalos Therapeutics Inc
Kalvista Pharmaceuticals Inc
Kanaph Therapeutics Inc
Kiora Pharmaceuticals Inc
Kodiak Sciences Inc
Kowa Co Ltd
Kubota Vision Inc
Kuur Therapeutics Ltd
Laboratorios Sophia SA de CV
Luye Pharma Group Ltd
Mabion SA
Mabwell Shanghai Bioscience Co Ltd
Molecular Partners AG
NeuMedics Inc
Novartis AG
Novelty Nobility Inc
Noveome Biotherapeutics Inc
Oak Hill Bio Inc
OccuRx Pty Ltd
Ocugen Inc
Ocular Therapeutix Inc
Oculis SA
OcuNexus Therapeutics Inc
OcuTerra Therapeutics Inc
Opthea Ltd
Outlook Therapeutics Inc
Oxular Ltd
Oxurion NV
PanOptica Inc
Phanes Therapeutics Inc
PharmAbcine Inc
Pleryon Therapeutics Ltd
Profarma
Qilu Pharmaceutical Co Ltd
Rebio Technologies Ltd
Regeneron Pharmaceuticals Inc
RemeGen Co Ltd
Rezolute Inc
RiniSight Inc
Ripple therapeutics Corp
Samsung Bioepis Co Ltd
Semathera Inc
Senju Pharmaceutical Co Ltd
Shanghai SIMR Biotech Co Ltd
Surrozen Inc
Suzhou Stainwei Biotech Inc
Targeted Therapy Technologies LLC
Theravance Biopharma Inc
Uni-Bio Science Group Ltd
Unity Biotechnology Inc
Verseon Corp
Xbrane Biopharma AB
YD Life Science Co
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Diabetic Macular Edema – Overview

Diabetic Macular Edema – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Diabetic Macular Edema – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diabetic Macular Edema – Companies Involved in Therapeutics Development

Diabetic Macular Edema – Drug Profiles

Diabetic Macular Edema – Dormant Projects

Diabetic Macular Edema – Discontinued Products

Diabetic Macular Edema – Product Development Milestones

Featured News & Press Releases

Mar 10, 2022: Health Canada approves Samsung Bioepis and Biogen’s BYOOVIZ (SB11), LUCENTIS biosimilar (ranibizumab)

Feb 22, 2022: Rezolute announces positive study results for RZ402, an oral PKI being developed for DME

Feb 14, 2022: UNITY Biotechnology announces additional data from phase 1 study of UBX1325 in advanced vascular eye disease

Feb 14, 2022: Oxurion announces new data on THR-149 phase 2 clinical trial (“KALAHARI”) in DME at the Angiogenesis, Exudation, and Degeneration 2022 Conference

Feb 11, 2022: Oxurion announces upcoming presentation on THR-149 phase 2 clinical trial (“KALAHARI”) at the Angiogenesis, Exudation, and Degeneration 2022 Conference

Feb 11, 2022: Roche announces presentation of new two-year data of Vabysmo at Angiogenesis, Exudation and Degeneration 2022 on 12 February

Feb 03, 2022: Kodiak Sciences completes enrollment in GLEAM and GLIMMER phase 3 clinical trials of KSI-301 in patients with diabetic macular edema

Jan 28, 2022: FDA approves Genentech’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss

Jan 24, 2022: The Lancet publishes studies showing Roche’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months

Jan 18, 2022: Osaikang subsidiary’s bio-innovative drug obtaining clinical trial approval notice

Jan 07, 2022: Oxurion provides update on THR-149

Jan 07, 2022: Oxurion provides update on THR-687

Dec 10, 2021: Novartis reports positive data from diabetic macular oedema trial of Beovu

Dec 09, 2021: Novartis announces positive results from year two of the Phase III trial of Beovu in diabetic macular edema

Nov 30, 2021: Isarna Therapeutics announces first patient enrolled in international phase 2a clinical study in ophthalmology indications Wet AMD and DME

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Diabetic Macular Edema, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Companies, 2022 (Contd..2)

Number of Products under Development by Companies, 2022 (Contd..3)

Number of Products under Development by Companies, 2022 (Contd..4)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Products under Development by Companies, 2022 (Contd..6)

Products under Development by Companies, 2022 (Contd..7)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Diabetic Macular Edema – Pipeline by 3SBio Inc, 2022

Diabetic Macular Edema – Pipeline by 4D Molecular Therapeutics Inc, 2022

Diabetic Macular Edema – Pipeline by Aadi Bioscience Inc, 2022

Diabetic Macular Edema – Pipeline by Abpro Corp, 2022

Diabetic Macular Edema – Pipeline by Aciont Inc, 2022

Diabetic Macular Edema – Pipeline by Aerie Pharmaceuticals Inc, 2022

Diabetic Macular Edema – Pipeline by Aldeyra Therapeutics Inc, 2022

Diabetic Macular Edema – Pipeline by Allegro Ophthalmics LLC, 2022

Diabetic Macular Edema – Pipeline by Allgenesis Biotherapeutics Inc, 2022

Diabetic Macular Edema – Pipeline by AmMax Bio Inc, 2022

Diabetic Macular Edema – Pipeline by Ampio Pharmaceuticals Inc, 2022

Diabetic Macular Edema – Pipeline by ANBITION Srl, 2022

Diabetic Macular Edema – Pipeline by Apexian Pharmaceuticals Inc, 2022

Diabetic Macular Edema – Pipeline by Araim Pharmaceuticals Inc, 2022

Diabetic Macular Edema – Pipeline by Ascentage Pharma Group International, 2022

Diabetic Macular Edema – Pipeline by AsclepiX Therapeutics Inc, 2022

Diabetic Macular Edema – Pipeline by Ashvattha Therapeutics LLC, 2022

Diabetic Macular Edema – Pipeline by AskGene Pharma Inc, 2022

Diabetic Macular Edema – Pipeline by Avirmax Inc, 2022

Diabetic Macular Edema – Pipeline by BetaStem Therapeutics Inc, 2022

Diabetic Macular Edema – Pipeline by Bio-Thera Solutions Ltd, 2022

Diabetic Macular Edema – Pipeline by BioCryst Pharmaceuticals Inc, 2022

Diabetic Macular Edema – Pipeline by Cell Care Therapeutics Inc, 2022

Diabetic Macular Edema – Pipeline by Celltrion Inc, 2022

Diabetic Macular Edema – Pipeline by Celon Pharma SA, 2022

Diabetic Macular Edema – Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, 2022

Diabetic Macular Edema – Pipeline by Chiome Bioscience Inc, 2022

Diabetic Macular Edema – Pipeline by Clearside BioMedical Inc, 2022

Diabetic Macular Edema – Pipeline by Curacle Co Ltd, 2022

Diabetic Macular Edema – Pipeline by Drive Therapeutics LLC, 2022

Diabetic Macular Edema – Pipeline by Elasmogen Ltd, 2022

Diabetic Macular Edema – Pipeline by Eluminex Biosciences Ltd, 2022

Diabetic Macular Edema – Pipeline by Everglades Biopharma LLC, 2022

Diabetic Macular Edema – Pipeline by Exonate Ltd, 2022

Diabetic Macular Edema – Pipeline by EyeGene Inc, 2022

Diabetic Macular Edema – Pipeline by F. Hoffmann-La Roche Ltd, 2022

Diabetic Macular Edema – Pipeline by Gene Signal International SA, 2022

Diabetic Macular Edema – Pipeline by GlaxoSmithKline Plc, 2022

Diabetic Macular Edema – Pipeline by Graybug Vision Inc, 2022

Diabetic Macular Edema – Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, 2022

Diabetic Macular Edema – Pipeline by Huabo Biopharm (Shanghai) Co Ltd, 2022

Diabetic Macular Edema – Pipeline by Huadong Medicine Co Ltd, 2022

Diabetic Macular Edema – Pipeline by Ikarovec Ltd, 2022

Diabetic Macular Edema – Pipeline by Innovent Biologics Inc, 2022

Diabetic Macular Edema – Pipeline by Isarna Therapeutics GmbH, 2022

Diabetic Macular Edema – Pipeline by Johnson & Johnson, 2022

Diabetic Macular Edema – Pipeline by Kala Pharmaceuticals Inc, 2022

Diabetic Macular Edema – Pipeline by Kalos Therapeutics Inc, 2022

Diabetic Macular Edema – Pipeline by Kalvista Pharmaceuticals Inc, 2022

Diabetic Macular Edema – Pipeline by Kanaph Therapeutics Inc, 2022

Diabetic Macular Edema – Pipeline by Kiora Pharmaceuticals Inc, 2022

Diabetic Macular Edema – Pipeline by Kodiak Sciences Inc, 2022

Diabetic Macular Edema – Pipeline by Kowa Co Ltd, 2022

Diabetic Macular Edema – Pipeline by Kubota Vision Inc, 2022

Diabetic Macular Edema – Pipeline by Kuur Therapeutics Ltd, 2022

Diabetic Macular Edema – Pipeline by Laboratorios Sophia SA de CV, 2022

Diabetic Macular Edema – Pipeline by Luye Pharma Group Ltd, 2022

Diabetic Macular Edema – Pipeline by Mabion SA, 2022

Diabetic Macular Edema – Pipeline by Mabwell Shanghai Bioscience Co Ltd, 2022

Diabetic Macular Edema – Pipeline by Molecular Partners AG, 2022

Diabetic Macular Edema – Pipeline by NeuMedics Inc, 2022

Diabetic Macular Edema – Pipeline by Novartis AG, 2022

Diabetic Macular Edema – Pipeline by Novelty Nobility Inc, 2022

Diabetic Macular Edema – Pipeline by Noveome Biotherapeutics Inc, 2022

Diabetic Macular Edema – Pipeline by Oak Hill Bio Inc, 2022

Diabetic Macular Edema – Pipeline by OccuRx Pty Ltd, 2022

Diabetic Macular Edema – Pipeline by Ocugen Inc, 2022

Diabetic Macular Edema – Pipeline by Ocular Therapeutix Inc, 2022

Diabetic Macular Edema – Pipeline by Oculis SA, 2022

Diabetic Macular Edema – Pipeline by OcuNexus Therapeutics Inc, 2022

Diabetic Macular Edema – Pipeline by OcuTerra Therapeutics Inc, 2022

Diabetic Macular Edema – Pipeline by Opthea Ltd, 2022

Diabetic Macular Edema – Pipeline by Outlook Therapeutics Inc, 2022

Diabetic Macular Edema – Pipeline by Oxular Ltd, 2022

Diabetic Macular Edema – Pipeline by Oxurion NV, 2022

Diabetic Macular Edema – Pipeline by PanOptica Inc, 2022

Diabetic Macular Edema – Pipeline by Phanes Therapeutics Inc, 2022

Diabetic Macular Edema – Pipeline by PharmAbcine Inc, 2022

Diabetic Macular Edema – Pipeline by Pleryon Therapeutics Ltd, 2022

Diabetic Macular Edema – Pipeline by Profarma, 2022

Diabetic Macular Edema – Pipeline by Qilu Pharmaceutical Co Ltd, 2022

Diabetic Macular Edema – Pipeline by Rebio Technologies Ltd, 2022

Diabetic Macular Edema – Pipeline by Regeneron Pharmaceuticals Inc, 2022

Diabetic Macular Edema – Pipeline by RemeGen Co Ltd, 2022

Diabetic Macular Edema – Pipeline by Rezolute Inc, 2022

Diabetic Macular Edema – Pipeline by RiniSight Inc, 2022

Diabetic Macular Edema – Pipeline by Ripple therapeutics Corp, 2022

Diabetic Macular Edema – Pipeline by Samsung Bioepis Co Ltd, 2022

Diabetic Macular Edema – Pipeline by Semathera Inc, 2022

Diabetic Macular Edema – Pipeline by Senju Pharmaceutical Co Ltd, 2022

Diabetic Macular Edema – Pipeline by Shanghai SIMR Biotech Co Ltd, 2022

Diabetic Macular Edema – Pipeline by Surrozen Inc, 2022

Diabetic Macular Edema – Pipeline by Suzhou Stainwei Biotech Inc, 2022

Diabetic Macular Edema – Pipeline by Targeted Therapy Technologies LLC, 2022

Diabetic Macular Edema – Pipeline by Theravance Biopharma Inc, 2022

Diabetic Macular Edema – Pipeline by Uni-Bio Science Group Ltd, 2022

Diabetic Macular Edema – Pipeline by Unity Biotechnology Inc, 2022

Diabetic Macular Edema – Pipeline by Verseon Corp, 2022

Diabetic Macular Edema – Pipeline by Xbrane Biopharma AB, 2022

Diabetic Macular Edema – Pipeline by YD Life Science Co, 2022

Diabetic Macular Edema – Pipeline by Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd, 2022

Diabetic Macular Edema – Dormant Projects, 2022

Diabetic Macular Edema – Dormant Projects, 2022 (Contd..1)

Diabetic Macular Edema – Dormant Projects, 2022 (Contd..2)

Diabetic Macular Edema – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Diabetic Macular Edema, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Diabetic Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Diabetic Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Diabetic Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.